

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

COV318

RRID:CVCL_2419

Type: Cell Line

Proper Citation

RRID:CVCL_2419

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2419

Proper Citation: RRID:CVCL_2419

Description: Cell line COV318 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:8436435](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32612269](#), [PMID:35918200](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COV318

Synonyms: Cov318, COV-318

Cross References: EFO:EFO_0006382, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:601, BioSample:SAMN03473267, BioSample:SAMN10987637, cancercellines:CVCL_2419, Cell_Model_Passport:SIDM01480, DepMap:ACH-000256, ECACC:07071903, EGA:EGAS00001000610, GEO:GSM313686, GEO:GSM886962, GEO:GSM888031, GEO:GSM1291133, GEO:GSM2474973, IARC_TP53:28345, LiGeA:CCLE_904,

PharmacDB:COV318_253_2019, PRIDE:PXD003668, Progenetix:CVCL_2419, Wikidata:Q54814339

ID: CVCL_2419

Record Creation Time: 20220427T215517+0000

Record Last Update: 20260920T001847+0000

Ratings and Alerts

No rating or validation information has been found for COV318.

No alerts have been found for COV318.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. Cancer research, 86(4), 1073.

Gjerde CH, et al. (2026) A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. EBioMedicine, 124, 106135.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications, 6(2), 383.

Hockings H, et al. (2025) Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. Cancer research, 85(18), 3503.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. Cell chemical biology, 32(4), 556.

Little S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. iScience, 28(6), 112555.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. *Cancer discovery*, 14(3), 446.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. *Cell reports*, 42(10), 113307.

Wong-Brown MW, et al. (2022) Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy. *BMC cancer*, 22(1), 100.

Lin J, et al. (2021) The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. *Cancer immunology research*, 9(12), 1413.

Kleinmanns K, et al. (2020) CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. *EBioMedicine*, 56, 102783.

Jung M, et al. (2020) ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. *International journal of cancer*, 147(8), 2225.

Kleinmanns K, et al. (2020) CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. *EBioMedicine*, 56, 102782.